Oppenheimer maintains Ensign Group at Outperform, raises price target to $215 from $210

Oppenheimer reaffirmed its Outperform rating for Ensign Group and increased its price target to $215 from $210, suggesting a 16.8% upside from the Oct 28 close. The firm cited the company's performance in its updated outlook.

Original reporting
Published Oct 29, 2026, 1:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Ensign Group at Outperform, raises price target to $215 from $210 — source image
Decision brief

The 30-second read

$ENSGBullishMed
01

Why it matters

The target increase signals a modest bullish bias, but without fresh earnings or news the move may be muted.

02

Market read

Analyst target raise provides a small trading cue; investors may test the new $215 level.

03

What to watch

No new fundamental data; price target may reflect broader market optimism rather than company-specific catalysts.

Relevance 6/10Novelty 6/10Timing: today

Background

Ensign Group is a specialty finance company; analyst coverage influences its valuation.

Company-level read

Ticker impact

$ENSGBullishMedium confidence
Context

Oppenheimer raised Ensign Group's price target to $215 from $210, indicating a new bullish outlook.

Expected impact

potential upside as investors price in the higher target

Evidence & confidence

The target increase suggests improved expectations, likely prompting buying pressure.

Market effects

May lift peer valuation in the specialty finance sector.

Limited to US markets where ENSG trades.

Low

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Oppenheimer

    Research firm that issued the upgraded price target.

  • Ensign Group

    Subject of the price target upgrade.

Related articles

$DHCMedAI 8/10

DHC Q3 2026 slides: SHOP segment surges 50% despite earnings miss

Diversified Healthcare Trust (DHC) reported Q3 2026 results with a net loss of $0.21 per share, missing estimates. Shares fell 2.58% to $7.54. The SHOP segment saw a 50.4% NOI increase, while medical office and life science faced challenges. DHC raised same-property NOI guidance but lowered EBITDAre and FFO guidance due to management fees. The company has $260.7M in liquidity and a debt-to-EBITDAre ratio of 8.2x.

$ENSGHighAI 8/10

ENSG Q3 deep dive: organic growth and acquisitions drive occupancy and margin gains

Ensign Group (ENSG) reported Q3 revenue of $1.48 billion, missing estimates by 7.1%, but beat adjusted EBITDA expectations. The company raised full-year revenue guidance to $5.91 billion and GAAP EPS guidance to $7.98. Occupancy and skilled mix gains, along with acquisitions, drove growth. Management highlighted clinical model success and market expansion, including entry into Florida.

$ENSGMed

Truist raises Ensign Group stock price target to $210 on margins

Truist Securities raised its price target on The Ensign Group (NASDAQ:ENSG) to $210 from $207, citing strong Q3 results with revenue of $5.67B and EBITDA of $621.52M. The company beat EPS estimates and raised fiscal 2026 guidance. Truist noted positive occupancy trends, labor commentary, and M&A activity. ENSG's Q3 revenue missed estimates but earnings exceeded expectations.

$ENSGHighAI 8/10

The Ensign Group Q3 Earnings Call Highlights

Ensign Group (ENSG) reported Q3 earnings, raising its full-year 2026 adjusted earnings guidance to $7.94-$8.02 per share and revenue outlook to $5.89-$5.92 billion. The company added 22 operations, including nine in Florida, and discussed turnaround efforts for acquired facilities. Ensign had $337.6 million in cash and $512.3 million in cash flow from operations as of Sept. 30, with $1 billion in available capital.

$ENSGHighAI 8/10

Ensign Group Inc (ENSG) Q3 2026 Earnings Call Highlights: Raised Guidance, Strong

Ensign Group Inc (ENSG) raised its 2026 guidance, citing strong occupancy and skilled mix growth. Challenges include integrating 22 new operations, particularly in Florida and Texas, which may take over a year to contribute positively. The company faces risks from reimbursement variations and litigation environments. CEO Barry Port noted strong clinical outcomes and managed care partnerships. CFO Suzanne Snapper highlighted $1B in available funds for growth.

$ENSGMedAI 8/10

Nursing Home Giant Ensign Touts $1B for Future Investments, Census Momentum and New CMS Survey Performance in 3Q

Ensign Group (ENSG) reported Q3 earnings of $2.03 per share, up 23.8% YoY, and revenue of $1.48B, up 14.5%. CEO Barry Port highlighted strong occupancy, skilled-mix growth, and improved CMS survey performance. The company raised full-year 2026 guidance and announced 22 new acquisitions. Ensign has $1B in cash and credit capacity for future investments.